Phase 2 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- The patient, or a legally authorised representative on their behalf, must be willing and able to give consent to take part in the study before it begins.
- The person must be willing to follow all study procedures and be available for the full length of the study.
- Adults aged 18 or older, of any gender.
- People who have a general health and function level at or above a certain threshold (called Karnofsky Performance Status ≥ 60), confirmed within 7 days before joining — this measures how well a person can carry out daily activities (confirm with trial site).
- People who have at least one brain metastasis (cancer that has spread to the brain) that measures between 2 cm and 5 cm across, confirmed by a brain scan. Multiple brain metastases are allowed under certain conditions — up to two larger ones (between 2–5 cm) may be treated in the study, and up to 10 additional smaller ones (under 2 cm) may also be treated. All tumours must be at least 5 mm away from certain structures in the eye pathway (the optic chiasm and optic nerves).
- People who have a known current or past invasive cancer that did not start in the brain, confirmed by a medical pathology report within the past 3 years.
- People who are medically able to tolerate the type of radiation treatment used in this study (called stereotactic radiosurgery, or SRS).
- People whose neurological condition is stable, meaning immediate surgery is not considered necessary or recommended.
- People who could potentially become pregnant must have a negative pregnancy test (urine or blood) within 7 days before joining the study. This applies to anyone who has had menstrual periods and has not had surgical removal of the uterus or ovaries, and is not post-menopausal.
- People who are sexually active must agree to use medically accepted contraception during the treatment period to prevent pregnancy.
Who may not be able to join:
- People who have previously had any radiation treatment to the brain, including whole-brain radiotherapy or SRS directed at the specific large tumour being treated in this study.
- People who show signs of a condition called leptomeningeal disease (LMD), where cancer has spread to the fluid or lining surrounding the brain and spinal cord, based on clinical, imaging, or laboratory findings (confirm with trial site for how this is assessed).
- People who are unable to have an MRI scan with contrast dye.
- People who are planned to receive systemic treatments such as chemotherapy or immunotherapy within 3 days before, on the same day as, or within 3 days after completing the SRS radiation treatment.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Charlotte Rivers, MD, Medical University of South Carolina
Phone: 843-792-9321
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Time to Composite unfavorable outcome (CUO) by (1) lack of local control (disease progression for any lesion treated on study); (2) the need for further intervention to the treated tumor; (3) radiation necrosis.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.